Alector vs Lineage Cell Therapeutics
Alector is the larger business, with $21.0m of revenue in fiscal 2025 against $14.6m for Lineage Cell Therapeutics (1.4 times as much). Lineage Cell Therapeutics grew faster (53.2% against -79.1%). Lineage Cell Therapeutics kept more of each dollar of sales as profit: a net margin of -436.5% against -679.2%.
| Latest fiscal year | AlectorALEC, 2025 | Lineage Cell TherapeuticsLCTX, 2025 |
|---|---|---|
| Revenue | $21.0m | $14.6m |
| Revenue growth | -79.1% | 53.2% |
| Net income | −$143m | −$63.5m |
| Operating margin | -741.3% | — |
| Net margin | -679.2% | -436.5% |
| Return on equity | -181.6% | -103.4% |
| Free cash flow | −$184m | −$19.4m |
| Cash | $65.8m | $40.8m |
| Total debt | $10.4m | $0 |
| Debt to equity | 33.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 103 | 77 |
| Market value | $229m | $252m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 21 (Weak) |
| Insider trades, 12 months | 0 buys, 21 sales | 1 buys, 0 sales |